Literature DB >> 26455434

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Subrahmanya D Vallabhapurapu1, Sunil K Noothi1, Derek A Pullum1, Charles H Lawrie2,3, Rachel Pallapati1, Veena Potluri1, Christian Kuntzen4, Sohaib Khan1, David R Plas1, Robert Z Orlowski5, Marta Chesi6, W Michael Kuehl7, P Leif Bergsagel6, Michael Karin8, Sivakumar Vallabhapurapu1.   

Abstract

Although transcriptional activation by NF-κB is well appreciated, physiological importance of transcriptional repression by NF-κB in cancer has remained elusive. Here we show that an HDAC4-RelB-p52 complex maintains repressive chromatin around proapoptotic genes Bim and BMF and regulates multiple myeloma (MM) survival and growth. Disruption of RelB-HDAC4 complex by a HDAC4-mimetic polypeptide blocks MM growth. RelB-p52 also represses BMF translation by regulating miR-221 expression. While the NIK-dependent activation of RelB-p52 in MM has been reported, we show that regardless of the activation status of NIK and the oncogenic events that cause plasma cell malignancy, several genetically diverse MM cells including Bortezomib-resistant MM cells are addicted to RelB-p52 for survival. Importantly, RelB is constitutively phosphorylated in MM and ERK1 is a RelB kinase. Phospho-RelB remains largely nuclear and is essential for Bim repression. Thus, ERK1-dependent regulation of nuclear RelB is critical for MM survival and explains the NIK-independent role of RelB in MM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26455434     DOI: 10.1038/ncomms9428

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  66 in total

1.  BCR-ABL1 expression in multiple myeloma cells: a case of mistaken identity?

Authors:  Roderick A F MacLeod; Stefan Nagel; Wilhelm Dirks; Hans G Drexler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

Review 2.  Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.

Authors:  Kian-Huat Lim; Yibin Yang; Louis M Staudt
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

3.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

4.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

5.  Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control.

Authors:  R Marienfeld; F Berberich-Siebelt; I Berberich; A Denk; E Serfling; M Neumann
Journal:  Oncogene       Date:  2001-12-06       Impact factor: 9.867

6.  The ERK Cascade: Distinct Functions within Various Subcellular Organelles.

Authors:  Inbal Wortzel; Rony Seger
Journal:  Genes Cancer       Date:  2011-03

Review 7.  NF-kappaB and cancer-identifying targets and mechanisms.

Authors:  Willscott E Naugler; Michael Karin
Journal:  Curr Opin Genet Dev       Date:  2008-04-24       Impact factor: 5.578

8.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

Review 9.  Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

Authors:  Jennifer L Thompson
Journal:  Ann Pharmacother       Date:  2013-01-08       Impact factor: 3.154

10.  Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.

Authors:  Brian J Zarnegar; Yaya Wang; Douglas J Mahoney; Paul W Dempsey; Herman H Cheung; Jeannie He; Travis Shiba; Xiaolu Yang; Wen-Chen Yeh; Tak W Mak; Robert G Korneluk; Genhong Cheng
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

View more
  30 in total

1.  Dynein light chain binding determines complex formation and posttranslational stability of the Bcl-2 family members Bmf and Bim.

Authors:  Prafull Kumar Singh; Aristomenis Roukounakis; Arnim Weber; Kushal Kumar Das; Benedicte Sohm; Andreas Villunger; Ana J Garcia-Saez; Georg Häcker
Journal:  Cell Death Differ       Date:  2019-06-12       Impact factor: 15.828

Review 2.  Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

3.  Alternative NF-κB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3.

Authors:  Yu Tao; Zhanjie Liu; Yingyong Hou; Shouli Wang; Sanhong Liu; Yuhang Jiang; Dan Tan; Qiulin Ge; Cuifeng Li; Yiming Hu; Zhi Liu; Xi Chen; Qi Wang; Mingliang Wang; Xiaoren Zhang
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

4.  Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy.

Authors:  Yuzhu Hou; Hua Liang; Enyu Rao; Wenxin Zheng; Xiaona Huang; Liufu Deng; Yuan Zhang; Xinshuang Yu; Meng Xu; Helena Mauceri; Ainhoa Arina; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  Immunity       Date:  2018-08-28       Impact factor: 31.745

Review 5.  The Prospective Application of Melatonin in Treating Epigenetic Dysfunctional Diseases.

Authors:  Seth Mikaye Monayo; Xin Liu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

6.  Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonization.

Authors:  Ryan H Moy; Alexander Nguyen; Jia Min Loo; Norihiro Yamaguchi; Christina M Kajba; Balaji Santhanam; Benjamin N Ostendorf; Y Gloria Wu; Saeed Tavazoie; Sohail F Tavazoie
Journal:  Dev Cell       Date:  2022-04-28       Impact factor: 13.417

Review 7.  Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.

Authors:  Takeshi Harada; Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2016-04-20       Impact factor: 2.490

8.  Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification.

Authors:  N Sanjib Banerjee; Dianne W Moore; Thomas R Broker; Louise T Chow
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-01       Impact factor: 11.205

9.  4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.

Authors:  Benjamin I Philipson; Roddy S O'Connor; Michael J May; Carl H June; Steven M Albelda; Michael C Milone
Journal:  Sci Signal       Date:  2020-03-31       Impact factor: 8.192

10.  E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-κB activation.

Authors:  Jie-Lin Duan; Hui-Qian He; Yao Yu; Tao Liu; Shu-Jun Ma; Fan Li; Yan-Shan Jiang; Xin Lin; De-Dong Li; Quan-Zhen Lv; Hui-Hui Ma; Xin-Ming Jia
Journal:  Sci Adv       Date:  2021-05-07       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.